In the rapidly expanding veterinary dermatology landscape, Zoetis Inc. is leaving an indelible pawprint. This US-based giant, whose expertise lies in delivering innovative vaccines and medications for both livestock and companion animals, is making waves in the sector with its ground-breaking products and dynamic growth strategy. One such disruptive innovation is the Apoquel Chewable (Tablet), which has metamorphosed the treatment landscape for pruritus and atopic dermatitis in dogs in the US. This development is not just a leap in veterinary medicine but a testament to the company’s pioneering spirit.
The veterinary dermatology market, valued at US$18.59 billion in 2024, is projected to grow at a strong compound annual growth rate (CAGR) of 8.5%. By 2025, it is expected to hit US$20.11 billion, eventually reaching an impressive US$30.31 billion by 2030. This sector encompasses therapeutic products that manage a spectrum of skin diseases in pets, ranging from allergies and infections to chronic skin disorders and skin cancer. The scope goes beyond mere treatment, with products that also maintain skin health, enhance coat quality, and overall animal wellbeing.
The growth trajectory is fuelled by a combination of factors. The surge in pet ownership and the expanding companion animal population have significantly increased the demand for specialized dermatological treatments. Additionally, the rising awareness about infectious zoonotic diseases, propelled by initiatives from government agencies and animal welfare organizations, is further driving the market forward. Moreover, the increasing uptake of pet insurance and a corresponding rise in animal healthcare expenditure is creating a fertile ground for continued expansion.
On the flip side, escalating pet care costs are posing a challenge, rendering advanced dermatology treatments less affordable for some pet owners. The mounting resistance to parasiticides is also affecting the effectiveness of common treatments, necessitating continuous innovation in dermatological solutions.
The veterinary dermatology market’s flourishing growth presents lucrative opportunities for companies like Zoetis Inc. For these companies to fully capitalize on this growth, strategic investments in research, product diversification, and global expansion will be crucial.
The US, with its robust pet healthcare infrastructure and high spending on animal health, is leading the North American veterinary dermatology market. Market behemoths like Zoetis Inc., Elanco Animal Health Incorporated, and Merck & Co., Inc., are driving innovation and ensuring the availability of effective treatment options. With a strong economy and increasing awareness of pet health, the US veterinary dermatology market is poised for significant growth from 2025 to 2030.
In the realm of administration, the topical segment commands the largest market share in the US veterinary dermatology market. Medicated shampoos, creams, ointments, and sprays, due to their ease of application and direct action on affected areas, are the go-to choices for veterinarians and pet owners alike.
As the veterinary dermatology market gallops towards unprecedented growth, companies like Zoetis Inc. are setting the pace, creating a future where our beloved pets enjoy the pinnacle of health and wellbeing.
Read more from theglobeandmail.com
